Hengrui, Affiliate Reistone In Apparent Dispute Over China Ivarmacitinib NDAs
Promises, Perils Of A Seemingly Dream Partnership
Executive Summary
The future fate of Jiangsu Hengrui’s new drug discovery and development subsidiary may provide some tips on what’s ahead for the Chinese biopharma sector.